BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33352385)

  • 1. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
    Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases.
    Zhang J; Wang Y; Liu Z; Wang L; Yao Y; Liu Y; Hao XZ; Wang J; Xing P; Li J
    Thorac Cancer; 2021 Dec; 12(24):3407-3415. PubMed ID: 34751504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
    Lavacchi D; Mazzoni F; Giaccone G
    Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
    Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
    Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
    Nagano T; Tachihara M; Nishimura Y
    Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
    Jung HA; Park S; Lee SH; Ahn JS; Ahn MJ; Sun JM
    ESMO Open; 2023 Dec; 8(6):102068. PubMed ID: 38016250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH; Soo RA
    Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
    Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA
    Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
    Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
    Tanaka H; Sakamoto H; Akita T; Ohyanagi F; Kawashima Y; Tambo Y; Tanimoto A; Horiike A; Miyauchi E; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
    Thorac Cancer; 2022 May; 13(10):1471-1478. PubMed ID: 35415873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.
    Pu X; Zhou Y; Kong Y; Chen B; Yang A; Li J; Li K; Xu Y; Wu L
    BMC Cancer; 2023 Oct; 23(1):982. PubMed ID: 37840124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
    J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
    Jänne PA; Ou SI; Kim DW; Oxnard GR; Martins R; Kris MG; Dunphy F; Nishio M; O'Connell J; Paweletz C; Taylor I; Zhang H; Goldberg Z; Mok T
    Lancet Oncol; 2014 Dec; 15(13):1433-1441. PubMed ID: 25456362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib.
    Kudo K; Kawakado K; Kawajiri T; Nishi T; Makimoto G; Tamura T; Kuyama S; Tanimoto M
    Intern Med; 2020 Jul; 59(14):1739-1740. PubMed ID: 32296006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?
    Bergonzini C; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
    Expert Opin Pharmacother; 2020 Aug; 21(11):1287-1298. PubMed ID: 32292093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
    Morita A; Hosokawa S; Yamada K; Umeno T; Kano H; Kayatani H; Shiojiri M; Sakugawa M; Bessho A
    Thorac Cancer; 2021 Apr; 12(8):1248-1251. PubMed ID: 33651475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
    Zhang B; Shi C; Gao Z; Zhong H; Xiong L; Gu A; Wang W; Chu T; Zhang W; Wang H; Zhang X; Zhong R; Han B
    BMC Cancer; 2022 Mar; 22(1):294. PubMed ID: 35305596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
    Cheng WC; Lin CC; Liao WC; Lin YC; Chen CH; Chen HJ; Tu CY; Hsia TC
    BMC Cancer; 2024 Feb; 24(1):228. PubMed ID: 38373960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
    Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.